Insider · CIK 0001853327

Burrows Scott L

Reports to the SEC for 2 companies · WALTHAM, MA

sec.gov

Transactions

Companies

Filings

CIK

0001853327

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-10-01	SYRESpyre Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−7,500 sh	—	—	312,357
2026-10-01	SYRESpyre Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−2,100 sh	$91.92	−$193K	83,062
2026-10-01	SYRESpyre Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,500 sh	$90.27	−$135K	85,162
2026-10-01	SYRESpyre Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−600 sh	$89.07	−$53.4K	86,662
2026-10-01	SYRESpyre Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+7,500 sh	$14.50	+$109K	87,262
2026-10-01	SYRESpyre Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−229 sh	$93.57	−$21.4K	79,762
2026-10-01	SYRESpyre Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−3,071 sh	$92.95	−$285K	79,991
2026-09-30	SYRESpyre Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−17.5K sh	—	—	319,857
2026-09-30	SYRESpyre Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−17.5K sh	$89.89	−$1.57M	79,762
2026-09-30	SYRESpyre Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+17.5K sh	$14.50	+$254K	97,262
2026-09-02	SYRESpyre Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−18.2K sh	$89.35	−$1.63M	79,762
2026-09-01	SYRESpyre Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+7,500 sh	$14.50	+$109K	105,494
2026-09-01	SYRESpyre Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−7,500 sh	—	—	337,357
2026-09-01	SYRESpyre Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−200 sh	$89.04	−$17.8K	97,994
2026-09-01	SYRESpyre Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−2,016 sh	$88.03	−$177K	98,194
2026-09-01	SYRESpyre Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−4,384 sh	$87.11	−$382K	100,210
2026-09-01	SYRESpyre Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−900 sh	$86.25	−$77.6K	104,594
2026-08-03	SYRESpyre Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−7,500 sh	—	—	344,857
2026-08-03	SYRESpyre Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−100 sh	$97.10	−$9,710	97,994
2026-08-03	SYRESpyre Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−2,300 sh	$96.30	−$221K	98,094
2026-08-03	SYRESpyre Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−5,100 sh	$95.21	−$486K	100,394
2026-08-03	SYRESpyre Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+7,500 sh	$14.50	+$109K	105,494
2026-07-01	SYRESpyre Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−7,500 sh	—	—	352,357
2026-07-01	SYRESpyre Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+7,500 sh	$14.50	+$109K	105,494
2026-07-01	SYRESpyre Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−5,775 sh	$87.55	−$506K	99,719
2026-07-01	SYRESpyre Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,725 sh	$88.37	−$152K	97,994
2026-06-25	SYRESpyre Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−5,000 sh	$87.12	−$436K	107,994
2026-06-25	SYRESpyre Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−10K sh	$87.14	−$871K	97,994
2026-06-25	SYRESpyre Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−15K sh	—	—	359,857
2026-06-25	SYRESpyre Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+15K sh	$14.50	+$218K	112,994
2026-06-01	SYRESpyre Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−2,599 sh	$70.77	−$184K	101,094
2026-06-01	SYRESpyre Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−3,100 sh	$72.06	−$223K	97,994
2026-06-01	SYRESpyre Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−7,500 sh	—	—	374,857
2026-06-01	SYRESpyre Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+7,500 sh	$14.50	+$109K	105,494
2026-06-01	SYRESpyre Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,801 sh	$69.75	−$126K	103,693
2026-05-01	SYRESpyre Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−12.5K sh	—	—	382,357
2026-05-01	SYRESpyre Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+12.5K sh	$14.50	+$181K	110,494
2026-05-01	SYRESpyre Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−12.5K sh	$71.37	−$892K	97,994
2026-04-01	SYRESpyre Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−6,200 sh	$49.21	−$305K	99,294
2026-04-01	SYRESpyre Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−7,500 sh	—	—	394,857
2026-04-01	SYRESpyre Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+7,500 sh	$14.50	+$109K	105,494
2026-04-01	SYRESpyre Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,300 sh	$49.98	−$65K	97,994
2026-03-03	SYRESpyre Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,500 sh	—	—	402,357
2026-03-03	SYRESpyre Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,500 sh	$14.50	+$36.3K	100,494
2026-03-03	SYRESpyre Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−2,300 sh	$40.56	−$93.3K	98,194
2026-03-03	SYRESpyre Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−200 sh	$41.66	−$8,332	97,994
2026-01-09	SYRESpyre Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+140K sh	—	—	140,000
2025-09-02	SYRESpyre Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−18.4K sh	$16.26	−$300K	97,994
2025-01-15	SYRESpyre Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+95.5K sh	—	—	95,500
2024-09-03	SYRESpyre Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−18.5K sh	$28.17	−$522K	116,422

Recent filings

Accepted (ET)
Oct 24
Burrows Scott L0001636282-26-000117
SEC(opens sec.gov)
Sep 34
Burrows Scott L0001636282-26-000109
SEC(opens sec.gov)
Aug 54
Burrows Scott L0001636282-26-000100
SEC(opens sec.gov)

Companies

Address

221 CRESCENT STREET, BUILDING 23, SUITE 105

WALTHAM, MA, 02453